N.B. Mehta and D.A. Yeowell of the Wellcome Foundation, Ltd. first patented bupropion HCl as an antidepressant in 1971. Since then, the drug has been marketed under the names Wellbutrin and Zyban. Bupropion works by an unknown mechanism, but is involved in the dopaminergic and noradrenergic systems. It is a weak inhibitor of neuronal uptake of norepinephrine, serotonin, and dopamine. Bupropion is marketed as Wellbutrin for the treatment of depression and attention deficit disorder and as Zyban (in stustained release form) for help in smoking cessation.
Lab name:
Common molecules
Sample provider:
Obtained courtesy of the Cambridge Structural Database
Reciprocal Net site software 0.9.1-50,
copyright (c) 2002-2009, The Trustees of Indiana University
Files and data presented via this software are property of their
respective owners.
Reciprocal Net is funded by the U.S. National Science Foundation as part of
the National Science Digital Library project.
